Immunotherapy with recombinant interleukin 2 may result in regression of metastatic cancer, particularly malignant melanoma and renal cell carcinoma.
We describe a patient who received interleukin 2 immunotherapy for metastatic renal cell carcinoma. After his second course of treatment, he developed a recurrence of pemphigus vulgaris that had been in remission for 10 years.
Interleukin 2 therapy may be associated with recurrence of an autoimmune disease, perhaps because of its ability to stimulate autoantibody production.(Arch Dermatol. 1994;130:890-893)
Prussick R, Plott RT, Stanley JR. Recurrence of Pemphigus Vulgaris Associated With Interleukin 2 Therapy. Arch Dermatol. 1994;130(7):890-893. doi:10.1001/archderm.1994.01690070084013